Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EEF1A1P6 (eukaryotic translation elongation factor 1 alpha 1 pseudogene 6) is one of 42 pseudogenes related to the EEF1A1 gene, dispersed throughout the human genome[1]. Pseudogenes are gene copies that usually do not produce functional proteins; they may regulate their parental genes through non-coding RNAs, miRNA decoy effects, or epigenetic modulation[3]. EEF1A1P6 was first reported in 1996 and is highly expressed in human primary monocytes, with additional associations found in datasets for hepatocellular carcinoma, schizophrenia, multiple myeloma, and rectum cancer, although its precise function and relevance in these diseases remain unknown[1]. No evidence exists for protein expression or direct involvement in cellular signaling or pathology, and it is not a recognized therapeutic target[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation elongation factor 1 alpha 1 pseudogene 6 (EEF1A1P6).